Variability in the measured response of bone to teriparatide

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

Calcium intake may be an important determinant of hip response.

Individuals vary in response to bone active agents, but that variability is poorly quantified and its basis is not well understood.

Who Took Part

The abstract describes 203 women taking part.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

This is a prospective study of change in bone mineral density and resorption biomarkers over a 12-month treatment period.

BMD response at spine and total hip was quantified by computing slopes for each participant's values, and biomarker change by the difference in values across the 12-month study period.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The timeline in the abstract includes 12 months.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Collagen Type I, Hip Joint and Hydroxyproline.

What This Means in Plain Language

The paper is a randomized study of Teriparatide in 203 women over 12 months.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.